TRIUMF & CNL SUCCESSFULLY PRODUCE RARE MEDICAL ISOTOPE THAT COULD REVOLUTIONIZE FIGHT AGAINST CANCER

Vancouver, BC and Chalk River, ON – October 23, 2019 – TRIUMF, Canada’s particle accelerator centre, and Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, are pleased to announce that they have completed the first joint production run of actinium-225, a rare medical isotope that shows great promise as the basis for new, cutting-edge cancer therapies. This accomplishment is a major milestone in making high-purity actinium-225, which is produced using TRIUMF’s high-energy cyclotron in Vancouver and processed at CNL’s Chalk River Laboratories in Ontario, more widely available for use in critical clinical trials.

Click here to go to the full story.